Financing - January 18, 2019
Bavarian Nordic announces exercise of 44 MUSD option by the US government
The U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine. The option, valued at USD 44 million, will cover qualification of the new fill-finish facility, currently being established at the company’s manufacturing site in Denmark, as well as transfer and validation of the […]
Financing - November 28, 2018
Cobra Biologics wins Innovate UK award
Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult win £1.5M innovate UK grant. Cobra Biologics has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency. Co-winners, Pall Corporation and the Cell and Gene Therapy Catapult will work with Cobra Biologics to investigate continuous manufacturing of adeno-associated virus (AAV) for gene therapy applications. “In […]
Financing - November 13, 2018
RetiPharma secures funding from the BII
RetiPharma has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII) to develop treatments of degenerative eye disorders. The funding will be used to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds using RetiPharma’s translational platform. RP001 is a new peptide drug […]
Financing - October 18, 2018
Alligator Bioscience receives government research grant
The company will receive a 500 000 SEK grant from Sweden’s government agency for innovation, Vinnova, for the project “Verification of the unique functionality of ATOR-1017 by 3D structure determination”. The project category was “Industrial pilot projects for neutron- and photon-based experiments at large-scale research infrastructures”. The grant will be used to obtain, in collaboration […]
Financing - October 16, 2018
Immunicum raises 352 MSEK
Immunicum raises SEK 351M in a directed issue and a fully guaranteed rights issue for continued clinical development of Ilixadencel – a new cancer immunotherapy. On 16 October 2018, the Board of Immunicum AB decided to implement a directed issue of approximately SEK 178M (the “Directed Issue”) and a fully guaranteed rights issue of approximately […]
Biotech Business - October 3, 2018
Quretech Bio takes its first external investor
The company has taken its first investment capital and a cunning business development partner. It is Nordiska Centrumhus that shares the Quretech Bio vision regarding new drugs against infectious diseases and antibiotic resistance by backing company growth in the region, reports Umeå Biotech Incubator. “We have gone from being a small intimate research-based company to […]
